|Strongbridge Biopharma plc -- USA Stock|| |
USD 6.75 0.10 1.50%
Founder and Sr. Clinical Advisor
We currently do not have informatin regarding Per MD. This executive tanure with Strongbridge Biopharma plc is not currenlty determined.
The company has return on total asset (ROA)
of (37.2) %
which means that it has lost $37.2 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (544.65) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 37.2 M in liabilities with Debt to Equity (D/E) ratio of 188.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Strongbridge Biopharma plc has Current Ratio of 4.61 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States, Sweden, and Cayman Islands. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania. Strongbridge Biopharma is traded on NASDAQ in USA.Strongbridge Biopharma plc (SBBP) is traded on NASDAQ in USA. It is located in PENNSYLVANIA, U.S.A and employs 24 people. Strongbridge Biopharma is listed under Pharmaceutical Products category by Fama And French industry classification.